Info

🌱 來自：Gene expression assay of Breast cancer

TAILORx

• Summary-of-TAILORx

Adjuvant Chemotherapy in Women with Midrange Recurrence Score of 21-Gene Breast Cancer Assay

1. Design:
   • Prospective trial
   • Multi-center
   • Randomized
2. Number of patients: 10,273 women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer
3. Patients characteristics:
   • Hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer
   • Midrange recurrence score of 11 to 25
4. Agent:
   • Endocrine therapy alone
   • Chemoendocrine therapy
5. Treatment line: Adjuvant therapy
6. Trial Name: TAILORx

Outcome	Endocrine therapy alone	Chemoendocrine therapy
Invasive DFS	Noninferior	Noninferior
HR	1.08 (95% CI, 0.94 to 1.24)	-
p-value	0.26	-
OS	Similar	Similar
Chemotherapy benefit DFS	50 < and score 16 to 25	-

8. Other findings in this trial:
   • Endocrine therapy and chemoendocrine therapy had similar efficacy in women with midrange 21-gene recurrence score.
   • Chemotherapy benefit varied with the combination of recurrence score and age.